ANTI-FRATAXIN CLONE 2F3 ZOOMAB« RABBIT MONOCLONAL (C005B-261428)

General description

We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies.Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Specificity

Clone 2F3 is a ZooMAb^® Rabbit recombinant monoclonal antibody that specifically detects Frataxin. It targets an epitope within 15 amino acids from the internal region.

Immunogen

KLH-conjugated linear peptide corresponding to 15 amino acids from the internal region of human Fraraxin.

Application

Quality Control Testing

Evaluated by Immunocytochemistry in K562 cells.

Immunocytochemistry Analysis: A 1:100 dilution of this antibody detected Frataxin in K562 cells.

Tested Applications

Western Blotting Analysis: A 1:10,000 dilution from a representative lot detected Frataxin in Human Kidney tissue lysate.

Enzyme Immunoassay Analysis (ELISA): Various dilution of this antibody from a representative lot detected recombinant Human Frataxin.

Affinity Binding Assay: A representative lot of this antibody bound Frataxin peptide with a KD of 3.5 x 10-7 in an affinity binding assay.

Immunohistochemistry (Paraffin) Analysis: A 1:1,000 dilution from a representative lot detected Frataxin in human kidney tissue sections.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Target description

Frataxin, mitochondrial (UniProt: Q16595; also known as EC:1.16.3.1, Friedreich ataxia protein, Fxn) is encoded by the FXN (also known as FRDA, X25) gene (Gene ID: 2395) in human. Frataxin is a highly conserved mitochondrial protein that promotes the biosynthesis of heme and assembly and repair of iron-sulfur clusters by delivering Fe2+ to proteins involved in these pathways. Human frataxin is shown to bind from six t seven iron ion. It is expressed in the heart, peripheral blood lymphocytes, and dermal fibroblasts. It is predominantly monomeric, but oligomeric forms are also present. It may play a role in the protection against iron-catalyzed oxidative stress through its ability to catalyze the oxidation of Fe2+ to Fe3+. The oligomeric form is reported to possess in vitro ferroxidase activity. As an iron chaperone protein, it is reported to protect mitochondrial aconitase [4Fe-4S]2+ cluster from disassembly and promote enzyme reactivation. Frataxin is synthesized with a transit peptide (aa 1-41) and it is processed in two steps by mitochondrial processing peptidase, which first cleaves the precursor to intermediate form (aa 42-210) and subsequently converts the intermediate to yield frataxin mature form (aa 81-210). The additional forms of frataxin (aa 56-210 and 78-210) are observed when the normal maturation process is impaired. Mature frataxin is a compact, globular protein containing an N-terminal helix, a middle β sheet region composed of seven strands, a second helix, and a C-terminal coil. The helices are folded upon the β sheet, with the C-terminal coil filling a groove between the two helices. Mutations in FXN gene are known to cause Friedreich ataxia, a progressive disease characterized by neurodegeneration and cardiomyopathy. This ZooMAb^® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Bulteau, A-L., et al. (2004). Science. 305(5681); 242-245; Yoon, T., and Cowan, JA. (2003). J. Am. Chem. Soc. 125(20); 6078-6084).

Physical form

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS, 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

Reconstitution

0.3 mg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Storage and Stability

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

Legal Information

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.